CANC Tema Oncology ETF

ETF on NASDAQ (US) · Actively managed · Listing

Form N-PORT Aug 31, 2026 vs May 31, 2026 Filed with the SEC Oct 30, 2026
Book +20% $176M → $211M
Line items (May 31, 2026: 57) 59
In top 10 41%
Largest holding: Revolution Medicines, Inc. ($12.7M) 6.0%
Portfolio date Aug 31, 2026
New / increased 7 / 37
Reduced / closed 14 / 5
Unchanged 0
−100%

Most notable sale · Nuvalent Inc

Nuvalent Inc sold out

Units went from 53,763 to 0 ($5.93M → $0). Was 3.4% of the May 31, 2026 portfolio.

+94%

Most notable buy · Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. raised by 94%

Shares went from 32,598 to 63,165 ($2.17M → $6.73M). Now 3.2% of the portfolio. Estimated trade $3.26M.

Largest holding: Revolution Medicines, Inc., cut 29%, 61,768 shares ($12.7M).

Revolution Medicines, Inc.: 6.0% Eli Lilly and Company: 5.2% Cogent Biosciences, Inc.: 4.7% Roche Holding AG: 4.2% Novartis AG: 3.8% Bristol-Myers Squibb Company: 3.6% Merck & Company, Inc.: 3.6% AbbVie Inc.: 3.3% Halozyme Therapeutics, Inc.: 3.2% Beone Medicines Ltd.: 3.2% The other 49 positions: 59.4% $211M Holdings value
Current positions Top 10 % of book
Revolution Medicines, Inc. RVMD $12.7M · −29% sh 6.0%
Eli Lilly and Company LLY $10.9M · +22% sh 5.2%
Cogent Biosciences, Inc. COGT $9.92M · +37% sh 4.7%
Roche Holding AG RHHBY $8.81M · +16% units 4.2%
Novartis AG NOVN $8.00M · +12% units 3.8%
Bristol-Myers Squibb Company BMY $7.54M · +11% sh 3.6%
Merck & Company, Inc. MRK $7.52M · −4% sh 3.6%
AbbVie Inc. ABBV $7.01M · +20% sh 3.3%
Halozyme Therapeutics, Inc. HALO $6.73M · +94% sh 3.2%
Beone Medicines Ltd. ONC $6.71M · +62% sh 3.2%

Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against May 31, 2026.

Healthcare: 91.7% Unclassified: 8.3% 1 sectors
Sectors % of holdings value
Healthcare 91.7%
Unclassified 8.3%
Biotechnology: 69.4% Drug Manufacturers - General: 20.7% Diagnostics & Research: 1.6% Unclassified: 8.3% 3 industries
Industries % of holdings value
Biotechnology 69.4%
Drug Manufacturers - General 20.7%
Diagnostics & Research 1.6%
Unclassified 8.3%
Initiations 7 Value
Kura Oncology, Inc. KURA 1.0% of portfolio $2.17M
Tango Therapeutics, Inc. TNGX 0.9% of portfolio $1.87M
Replimune Group, Inc. REPL 0.8% of portfolio $1.66M
Candel Therapeutics, Inc. CADL 0.5% of portfolio $1.13M
Bicara Therapeutics Inc. BCAX 0.4% of portfolio $867K
Moderna, Inc. MRNA 0.3% of portfolio $736K
Autolus Therapeutics plc AUTL 0.3% of portfolio $630K
Increases 37 Change
Halozyme Therapeutics, Inc. HALO $2.17M → $6.73M +94%
Cogent Biosciences, Inc. COGT $7.22M → $9.92M +37%
Beone Medicines Ltd. ONC $3.31M → $6.71M +62%
Eli Lilly and Company LLY $8.49M → $10.9M +22%
Tyra Biosciences, Inc. TYRA $527K → $2.14M 5.4x
Johnson & Johnson JNJ $4.48M → $6.53M +23%
Roche Holding AG RHHBY $7.42M → $8.81M +16%
AbbVie Inc. ABBV $4.94M → $7.01M +20%
Erasca, Inc. ERAS $1.90M → $3.72M +41%
Iovance Biotherapeutics, Inc. IOVA $1.15M → $3.30M +44%
Enliven Therapeutics, Inc. ELVN $2.30M → $4.31M +28%
Novartis AG NOVN $7.10M → $8.00M +12%
Reductions 14 Change
Revolution Medicines, Inc. RVMD $13.6M → $12.7M −29%
Immunome, Inc. IMNM $6.89M → $6.33M −27%
AstraZeneca AZN $6.23M → $4.21M −22%
ZAI Lab Limited ZLAB $3.48M → $4.11M −18%
BridgeBio Pharma, Inc. BBIO $4.85M → $4.92M −12%
ArriVent BioPharma, Inc. AVBP $1.29M → $653K −49%
Celcuity Inc. CELC $6.31M → $3.82M −10%
Amgen Inc. AMGN $3.71M → $4.34M −8%
Inhibrx Biosciences, Inc. INBX $1.06M → $898K −30%
Guardant Health, Inc. GH $1.42M → $1.40M −20%
Syndax Pharmaceuticals, Inc. SNDX $1.41M → $1.06M −24%
Merck & Company, Inc. MRK $6.29M → $7.52M −4%
Terminations 5 Change
Nuvalent Inc NUVL was $5.93M −100%
Regeneron Pharmaceuticals, Inc. REGN was $1.31M −100%
Chugai Pharmaceutical Co., Ltd. 4519 was $1.17M −100%
Hutchmed (China) Limited HCM was $777K −100%
SELLAS Life Sciences Group, Inc. SLS was $379K −100%

The other 2 reductions

First Tracks Biotherapeutics, Inc. (−1%), Gilead Sciences, Inc. (−<1%)

Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Aug 31, 2026 (Form N-PORT) vs the portfolio of May 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

Tema Oncology ETF (the "Fund") seeks to provide long-term growth.

Principal investment strategies

Under normal circumstances, the Fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The Tema ETF LLC (the "Adviser"), the Fund's investment adviser, will use internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms, diagnostic focused businesses with products used to diagnose cancer (such as liquid biopsies or cancer genomic screening), medical device companies focused on cancer treatment, and healthcare service providers with a specific strategic focus on helping treat and manage cancer. 1 The Fund generally is expected to consist of more than 15 companies but not more than 100 companies. The number of constituents may change depending on the number of companies available for investment that meet the Fund's criteria. To be eligible for inclusion in the Fund, a company must have a market capitalization of at least $100 million and there is no upper limit on the market capitalization of a portfolio company. To be eligible for inclusion in the Fund, a company must have a three-month average daily traded value of at least $500,000. A significant portion of the Fund's assets are expected to be invested in the United States and Europe. The Fund will not engage in currency hedging and is expected to own foreign currency for short periods of time for the purposes of buying and selling non-US listed securities and collecting dividends and/or coupon payments from those securities. The Fund is classified as a "non-diversified" investment company under the Investment Company Act of 1940, as amended (the "1940 Act"), which means that it may invest a high percentage of its assets in a limited number of issuers. The basic investment philosophy of the Adviser is to seek to invest in companies within the aforementioned thematic universe that are attractively valued when compared to their fundamentals and growth opportunities. The Adviser's security selection process for identifying companies within the aforementioned theme uses both "top down" idea generation (sector, theme, company research) and "bottom up" security selection (valuation, fundamental, quantitative, qualitative measures) approaches. In practice "top down" idea generation means fundamental sector research, quantitative tools (for example screening based on metrics such as five-year historic revenue growth, margins, or returns on invested capital) and the Adviser's own expertise, are used to narrow down the specific thematic research universe. Once this is defined "bottom up" security analysis involves the Adviser comparing valuation multiples (such as free cash flow yield, price to book ratio and price to earnings ratio or enterprise value to total invested capital, among others) to fundamental metrics (such as organic revenue growth, margins, returns on invested capital and equity, among others). Investments are deemed attractively valued when compared to fundamentals if the valuation multiples are below and fundamentals are above either (1) peers (2) the companies own historic averages (3) or prospective forecasts (as determined by the Adviser). Buttressing this is a detailed fundamental research profile of each company assessing business model, competitive edge, management incentives and track record, and balance sheet. The Adviser integrates environmental, social and corporate governance ("ESG") considerations into its investment analysis. This is in support of both the objective of maximizing return and the broader analysis of risks associated with individual companies.

Management and Contact

Adviser
Tema ETFs LLC
Sub-adviser
Tidal Investments LLC
Portfolio managers

Maurits Pot, Yuri Khodjamirian, and David Song (all since inception, August 2023).

Sub-Adviser – Tidal Investments LLC.

Portfolio Managers – Qiao Duan and Andy Hicks (since February 2026).

Phone
1.888.744.1377

Track Record as of Feb 28, 2026

1 Year Since Inception
Return Before Taxes 42.78% 16.09%
Return After Taxes on Distributions 42.76% 15.44%
Return After Taxes on Distributions and Sale of Fund Shares 25.34% 12.21%
S&P 500 Total Return Index 17.88% 21.05%

Holdings as of Aug 31, 2026

59 lines, 56 linked, weights sum to 100.05% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
Revolution Medicines Inc RVMD US76155X1000 Equity 61,768 −24,682 6.02% $ 12.698M
Eli Lilly & Co LLY US5324571083 Equity 9,404 +1,720 5.15% $ 10.878M
Cogent Biosciences Inc COGT US19240Q2012 Equity 283,440 +77,021 4.70% $ 9.92M
Roche Holding AG
RHHBY US7711951043 Equity 164,068 +22,415 4.17% $ 8.81M
Novartis AG
NOVN CH0012005267 Equity 52,465 +5,445 3.79% $ 8M
Bristol-Myers Squibb Co BMY US1101221083 Equity 112,924 +11,244 3.57% $ 7.544M
Merck & Co Inc MRK US58933Y1055 Equity 50,878 −2,100 3.56% $ 7.518M
AbbVie Inc ABBV US00287Y1091 Equity 27,338 +4,638 3.32% $ 7.01M
Halozyme Therapeutics Inc HALO US40637H1095 Equity 63,165 +30,567 3.19% $ 6.726M
BeOne Medicines Ltd ONC US07725L1026 Equity 18,669 +7,164 3.18% $ 6.713M
Johnson & Johnson JNJ US4781601046 Equity 24,555 +4,655 3.09% $ 6.528M
Immunome Inc IMNM US45257U1088 Equity 230,958 −84,690 3.00% $ 6.331M
Genmab A/S GMAB US3723032062 Equity 183,357 +24,496 2.88% $ 6.08M
CG oncology Inc CGON US1569441009 Equity 77,547 +8,845 2.76% $ 5.828M
Ideaya Biosciences Inc IDYA US45166A1025 Equity 142,271 +6,424 2.70% $ 5.705M
Exelixis Inc EXEL US30161Q1040 Equity 101,461 +4,576 2.63% $ 5.544M
Bridgebio Pharma Inc BBIO US10806X1028 Equity 64,261 −8,930 2.33% $ 4.922M
Amgen Inc AMGN US0311621009 Equity 10,097 −922 2.06% $ 4.34M
Enliven Therapeutics Inc ELVN US29337E1029 Equity 74,478 +16,281 2.04% $ 4.312M
AstraZeneca PLC AZN GB0009895292 Equity 25,983 −7,518 2.00% $ 4.214M
Legend Biotech Corp LEGN US52490G1022 Equity 197,934 +3,842 1.95% $ 4.113M
Zai Lab Ltd ZLAB US98887Q1040 Equity 161,278 −35,694 1.95% $ 4.106M
Celcuity Inc CELC US15102K1007 Equity 42,837 −4,613 1.81% $ 3.815M
Erasca Inc ERAS US29479A1088 Equity 208,197 +60,369 1.76% $ 3.723M
Relay Therapeutics Inc RLAY US75943R1023 Equity 185,142 +24,066 1.61% $ 3.403M
Iovance Biotherapeutics Inc IOVA US4622601007 Equity 403,718 +123,670 1.56% $ 3.298M
Zymeworks Inc ZYME US98985Y1082 Equity 110,609 +4,994 1.54% $ 3.253M
Nuvation Bio Inc NUVB US67080N1019 Equity 416,638 +21,325 1.31% $ 2.775M
UroGen Pharma Ltd URGN IL0011407140 Equity 61,279 +2,761 1.25% $ 2.641M
Arcus Biosciences Inc RCUS US03969F1093 Equity 87,067 +3,927 1.21% $ 2.549M
Kura Oncology Inc KURA US50127T1097 Equity 171,385 new +171,385 1.03% $ 2.168M
Gilead Sciences Inc GILD US3755581036 Equity 14,646 −46 1.02% $ 2.143M
Tyra Biosciences Inc TYRA US90240B1061 Equity 85,323 +69,543 1.01% $ 2.136M
Summit Therapeutics Inc SMMT US86627T1088 Equity 150,035 +28,938 0.97% $ 2.043M
Corvus Pharmaceuticals Inc CRVS US2210151005 Equity 142,722 +34,245 0.95% $ 2.004M
Natera Inc NTRA US6323071042 Equity 6,084 +1,846 0.93% $ 1.959M
Tango Therapeutics Inc TNGX US87583X1090 Equity 81,952 new +81,952 0.89% $ 1.872M
AnaptysBio Inc ANAB US0327241065 Equity 32,744 +1,474 0.88% $ 1.867M
Immatics NV IMTX NL0015285941 Equity 179,617 +8,118 0.81% $ 1.712M
Replimune Group Inc REPL US76029N1063 Equity 108,413 new +108,413 0.79% $ 1.659M
Immunocore Holdings PLC IMCR US45258D1054 Equity 44,900 +14,051 0.77% $ 1.631M
Cullinan Therapeutics Inc CGEM US2300311063 Equity 65,785 +2,959 0.69% $ 1.452M
Guardant Health Inc GH US40131M1099 Equity 8,773 −2,213 0.66% $ 1.395M
ORIC Pharmaceuticals Inc ORIC US68622P1093 Equity 99,043 +41,066 0.61% $ 1.287M
Candel Therapeutics Inc CADL US1374041093 Equity 86,337 new +86,337 0.53% $ 1.128M
Syndax Pharmaceuticals Inc SNDX US87164F1057 Equity 54,962 −17,250 0.50% $ 1.06M
Janux Therapeutics Inc JANX US47103J1051 Equity 53,953 +2,431 0.47% $ 983.024K
Inhibrx Biosciences Inc INBX US45720N1037 Equity 7,084 −3,086 0.43% $ 897.543K
Olema Pharmaceuticals Inc OLMA US68062P1066 Equity 83,532 +3,773 0.41% $ 871.239K
Bicara Therapeutics Inc BCAX US0554771032 Equity 37,499 new +37,499 0.41% $ 866.977K
BridgeBio Oncology Therapeutic BBOT US1079241022 Equity 97,750 +4,411 0.41% $ 860.2K
CytomX Therapeutics Inc CTMX US23284F1057 Equity 241,337 +12,350 0.38% $ 810.892K
Arvinas Inc ARVN US04335A1051 Equity 88,095 +3,971 0.38% $ 810.474K
First American Treasury Obliga
FXFXX US31846V3289 Money market 807,908.68 −1,112,400.27 0.38% $ 807.909K
First Tracks Biotherapeutics I TRAX US3371851029 Equity 19,205 −39,214 0.38% $ 803.537K
Moderna Inc MRNA US60770K1079 Equity 5,247 new +5,247 0.35% $ 736.364K
Adlai Nortye Group Ltd ANL US00704R1095 Equity 46,444 +2,090 0.31% $ 659.04K
ArriVent Biopharma Inc AVBP US04272N1028 Equity 21,729 −21,015 0.31% $ 652.956K
Autolus Therapeutics PLC AUTL US05280R1005 Equity 268,127 new +268,127 0.30% $ 630.098K

Trades May 31, 2026 to Aug 31, 2026

Holding Ticker Action Before After Change Value
Nuvalent Inc
NUVL Closed 53,763 — −53,763 $ -5.935M
Revolution Medicines Inc RVMD Sold 86,450 61,768 −24,682 $ -5.074M
Halozyme Therapeutics Inc HALO Bought 32,598 63,165 +30,567 $ 3.255M
Cogent Biosciences Inc COGT Bought 206,419 283,440 +77,021 $ 2.696M
BeOne Medicines Ltd ONC Bought 11,505 18,669 +7,164 $ 2.576M
Immunome Inc IMNM Sold 315,648 230,958 −84,690 $ -2.321M
Kura Oncology Inc KURA New — 171,385 +171,385 $ 2.168M
Eli Lilly & Co LLY Bought 7,684 9,404 +1,720 $ 1.99M
Tango Therapeutics Inc TNGX New — 81,952 +81,952 $ 1.872M
Tyra Biosciences Inc TYRA Bought 15,780 85,323 +69,543 $ 1.741M
Replimune Group Inc REPL New — 108,413 +108,413 $ 1.659M
First Tracks Biotherapeutics I TRAX Sold 58,419 19,205 −39,214 $ -1.641M
Regeneron Pharmaceuticals Inc REGN Closed 2,138 — −2,138 $ -1.314M
Johnson & Johnson JNJ Bought 19,900 24,555 +4,655 $ 1.238M
AstraZeneca PLC AZN Sold 33,501 25,983 −7,518 $ -1.219M
Roche Holding AG
RHHBY Bought 141,653 164,068 +22,415 $ 1.204M
AbbVie Inc ABBV Bought 22,700 27,338 +4,638 $ 1.189M
Chugai Pharmaceutical Co Ltd 4519 Closed 23,697 — −23,697 $ -1.174M
Candel Therapeutics Inc CADL New — 86,337 +86,337 $ 1.128M
Erasca Inc ERAS Bought 147,828 208,197 +60,369 $ 1.079M
Iovance Biotherapeutics Inc IOVA Bought 280,048 403,718 +123,670 $ 1.01M
Enliven Therapeutics Inc ELVN Bought 58,197 74,478 +16,281 $ 942.507K
Zai Lab Ltd ZLAB Sold 196,972 161,278 −35,694 $ -908.769K
Bicara Therapeutics Inc BCAX New — 37,499 +37,499 $ 866.977K
Novartis AG
NOVN Bought 47,020 52,465 +5,445 $ 830.272K
Genmab A/S GMAB Bought 158,861 183,357 +24,496 $ 812.287K
HUTCHMED China Ltd HCM Closed 67,823 — −67,823 $ -776.573K
Bristol-Myers Squibb Co BMY Bought 101,680 112,924 +11,244 $ 751.212K
Moderna Inc MRNA New — 5,247 +5,247 $ 736.364K
Bridgebio Pharma Inc BBIO Sold 73,191 64,261 −8,930 $ -683.949K
CG oncology Inc CGON Bought 68,702 77,547 +8,845 $ 664.79K
ArriVent Biopharma Inc AVBP Sold 42,744 21,729 −21,015 $ -631.501K
Autolus Therapeutics PLC AUTL New — 268,127 +268,127 $ 630.098K
Natera Inc NTRA Bought 4,238 6,084 +1,846 $ 594.338K
ORIC Pharmaceuticals Inc ORIC Bought 57,977 99,043 +41,066 $ 533.447K
Immunocore Holdings PLC IMCR Bought 30,849 44,900 +14,051 $ 510.332K
Corvus Pharmaceuticals Inc CRVS Bought 108,477 142,722 +34,245 $ 480.8K
Relay Therapeutics Inc RLAY Bought 161,076 185,142 +24,066 $ 442.333K
Celcuity Inc CELC Sold 47,450 42,837 −4,613 $ -410.834K
Amgen Inc AMGN Sold 11,019 10,097 −922 $ -396.349K
Summit Therapeutics Inc SMMT Bought 121,097 150,035 +28,938 $ 394.136K
Inhibrx Biosciences Inc INBX Sold 10,170 7,084 −3,086 $ -390.996K
SELLAS Life Sciences Group Inc SLS Closed 40,702 — −40,702 $ -378.936K
Guardant Health Inc GH Sold 10,986 8,773 −2,213 $ -351.911K
Syndax Pharmaceuticals Inc SNDX Sold 72,212 54,962 −17,250 $ -332.753K
Merck & Co Inc MRK Sold 52,978 50,878 −2,100 $ -310.296K
Ideaya Biosciences Inc IDYA Bought 135,847 142,271 +6,424 $ 257.602K
Exelixis Inc EXEL Bought 96,885 101,461 +4,576 $ 250.033K
Zymeworks Inc ZYME Bought 105,615 110,609 +4,994 $ 146.874K
Nuvation Bio Inc NUVB Bought 395,313 416,638 +21,325 $ 142.025K
UroGen Pharma Ltd URGN Bought 58,518 61,279 +2,761 $ 118.971K
Arcus Biosciences Inc RCUS Bought 83,140 87,067 +3,927 $ 114.983K
AnaptysBio Inc ANAB Bought 31,270 32,744 +1,474 $ 84.062K
Legend Biotech Corp LEGN Bought 194,092 197,934 +3,842 $ 79.837K
Immatics NV IMTX Bought 171,499 179,617 +8,118 $ 77.365K
Cullinan Therapeutics Inc CGEM Bought 62,826 65,785 +2,959 $ 65.305K
Janux Therapeutics Inc JANX Bought 51,522 53,953 +2,431 $ 44.293K
CytomX Therapeutics Inc CTMX Bought 228,987 241,337 +12,350 $ 41.496K
Olema Pharmaceuticals Inc OLMA Bought 79,759 83,532 +3,773 $ 39.352K
BridgeBio Oncology Therapeutic BBOT Bought 93,339 97,750 +4,411 $ 38.817K
Arvinas Inc ARVN Bought 84,124 88,095 +3,971 $ 36.533K
Adlai Nortye Group Ltd ANL Bought 44,354 46,444 +2,090 $ 29.657K
Gilead Sciences Inc GILD Sold 14,692 14,646 −46 $ -6,731.64

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up